Structure of α-Helical Membrane-bound Human Islet Amyloid Polypeptide and Its Implications for Membrane-mediated Misfolding*

Melania Apostolidou†, Sajith A. Jayasinghe§, and Ralf Langen††

From the †Department of Biochemistry and Molecular Biology, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, California 90033 and §Department of Chemistry and Biochemistry, California State University, San Marcos, California 92096

Human islet amyloid polypeptide (hIAPP) misfolding is thought to play an important role in the pathogenesis of type II diabetes mellitus. It has recently been shown that membranes can catalyze the misfolding of hIAPP via an α-helical intermediate of unknown structure. To better understand the mechanism of membrane-mediated misfolding, we used site-directed spin labeling and EPR spectroscopy to generate a three-dimensional structural model of this membrane-bound form. We find that hIAPP forms a single α-helix encompassing residues 9–22. The helix is flanked by N- and C-terminal regions that do not take up a clearly detectable secondary structure and are less ordered. Residues 21 and 22 are located in a transitional region between the α-helical structure and C terminus and exhibit significant mobility. The α-helical structure presented here has important implications for membrane-mediated aggregation. Anchoring hIAPP to the membrane not only increases the local concentration but also reduces the encounter between peptides to essentially a two-dimensional process. It is significant to note that the α-helical membrane-bound form leaves much of an important amyloidogenic region of hIAPP (residues 20–29) exposed for misfolding. Misfolding of this and other regions is likely further aided by the low dielectric environment near the membrane that is known to promote secondary structure formation. Based upon these considerations, a structural model for membrane-mediated aggregation is discussed.

Protein misfolding and amyloid fibril formation are common characteristics of a number of debilitating human diseases, such as Alzheimer disease, Parkinson disease, and type II diabetes mellitus (1, 2). In type II diabetes mellitus, the primary amyloidogenic agent is human islet amyloid polypeptide (hIAPP), a 37-residue peptide that is synthesized in pancreatic islet β-cells and co-secreted with insulin. A number of findings support the notion that hIAPP misfolding plays an important role in disease. Approximately 95% of all patients with type II diabetes mellitus have large extracellular deposits composed of fibrillar hIAPP (2, 3). In vitro studies have shown that hIAPP is toxic when exogenously added to cultured human islet β-cells (4–6) and that overexpression of hIAPP in COS cells results in accumulation of peptide aggregates and cell death (7, 8). Mouse and rat IAPP do not misfold and are not toxic to cultured cells, suggesting that misfolding is a prerequisite for IAPP toxicity. Furthermore, mice and rats do not naturally develop type II diabetes mellitus, but transgenic mice and rats that express hIAPP form amyloid deposits and exhibit signs of diabetes, especially when expression occurs in a background of obesity (9–13).

Like other amyloidogenic peptides and proteins, hIAPP misfolds via a nucleation-dependent aggregation pathway in which small oligomeric assemblies precede the formation of mature amyloid fibrils (14). Biological membranes play two important roles in this process (for review, see Ref. 15). First, membranes are thought to be targets of toxicity because oligomers of hIAPP (as well as other amyloid proteins) disrupt membrane integrity and thereby cause toxicity (4, 16–19). Second, membranes can act as catalysts of misfolding (20–28). It has recently been shown that hIAPP interacts with negatively charged membranes and that this interaction can dramatically accelerate misfolding, which reduces the time of aggregation and fibril formation from days to just a few minutes under optimal conditions (24, 29). The degree of acceleration strongly depends on ionic strength and the density of negatively charged lipids, suggesting that electrostatic interactions are important for membrane-mediated aggregation.

Circular dichroism (CD) and thioflavin T fluorescence data have demonstrated that this membrane-mediated misfolding occurs via an α-helical intermediate (29, 30). It has been estimated that ~15–20 amino acids participate in α-helix formation. What remains unknown, however, are the structure of this α-helical form, the number of helices that are formed, the specific residues that participate in helix formation, and the membrane topography.

Here, we employed a combination of site-directed spin labeling, EPR spectroscopy, and molecular modeling to generate a three-dimensional model of α-helical, membrane-bound hIAPP. We found that membrane-bound hIAPP has a central
helical region from residue 9 to residue 22, whereas the N- and C-terminal regions are much less ordered. This structure leaves much of the highly amyloidogenic stretch from residue 20 to residue 29 exposed for misfolding and β-sheet formation.

**EXPERIMENTAL PROCEDURES**

**Preparation of Spin-labeled hIAPP Derivatives**—Spin-labeled hIAPP derivatives were generated through specific cysteine labeling. As in our previous study, the native cysteine residues at positions 2 and 7 were substituted with alanine (31). Using CD and thioflavin T fluorescence, we verified that this Cys-less hIAPP had aggregation properties similar to that of wild type. Single-cysteine mutants were generated using peptide synthesis and obtained from Biomer Technology, LLC (Concord, CA). Lyophilized peptides were dissolved in DMSO and Milli-Q water and were reacted with 3 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine (POPS) (Avanti Polar Lipids) harboring spin labels at the 5, 7, and 10 positions on the acyl chains, as described previously (32). Using the spin-labeled phosphatidylcholines specified above, we found that a = 6.5 and b = 3.5.

**RESULTS**

**Mobility Analysis Reveals Local Structural Ordering upon Membrane Interaction**—To obtain detailed structural information on the α-helical, membrane-bound form of hIAPP, we generated 29 R1-labeled derivatives of hIAPP and recorded the EPR spectra of each spin-labeled derivative in solution and when bound to phospholipid membranes. As shown for the representative example of 9R1 (hIAPP labeled at position 9), the EPR spectra of all freshly dissolved derivatives are characterized by sharp and narrowly spaced lines that are indicative of high mobility (Fig. 1A, gray). These spectra are in agreement with previous data (31) and reflect the highly dynamic structure of the fast tumbling, monomeric hIAPP.

To record the EPR spectra of α-helical, membrane-bound hIAPP, it was important to choose conditions under which no aggregation or β-sheet formation would occur during the time course of the EPR measurements (several minutes). It had previously been shown that the α-helical form can be trapped kinetically and kept stable for several hours at low ionic strength in the presence of highly negatively charged vesicles (29). Under such conditions (80%POPS/20% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), we generated the membrane-bound, α-helical form of all spin-labeled derivatives. As shown for the example of 9R1 in Fig. 1A (black), membrane interaction causes a significant reduction in mobility, as indicated by the broadened lines and the concomitant reduction in signal amplitude. This spectral change reflects reduced tumbling and increased structural ordering upon membrane interaction. No spectral change could be observed over a period of 4 h (Fig. 1A, red), in agreement with CD and thioflavin data indicating that the α-helical structure remains stable for at least 24 h before misfolding and aggregation occurs (data not shown).

The EPR spectra of the α-helical, membrane-bound forms of all 29 spin-labeled hIAPP derivatives are shown in Fig. 1B. Although membrane interaction causes a reduction in mobility at all sites, the degree of this immobilization varies from site to site. The most pronounced ordering can be observed for residues 9–20. Spectra for these sites have characteristic line shapes and inverse central line width values (between 0.36 and 0.32 Gauss⁻¹) typically observed on surfaces of ordered structures (Fig. 2). In contrast, the soluble peptides have inverse central line width values between 0.62 and 0.68 Gauss⁻¹. Despite the clear decrease in mobility, none of these spectra exhibit any strongly immobilized components that would typically be observed at buried sites. Thus, residues 9–20 do not exhibit strong tertiary or quaternary packing interactions. Although some reduction in mobility can also be observed for sites in the N- and C-terminal regions, those sites still contain components of high mobility, indicating a less ordered state.
Accessibility Analysis Reveals the Formation of an Amphipathic Helix That Is Located Parallel to the Membrane Surface—Although the mobility data indicate the ordering of a central region, they do not provide information as to secondary structure or membrane topography. To obtain such information, we determined the accessibility of all spin-labeled sites to the paramagnetic colliders O₂ and NiEDDA. These measurements are based on the fact that the hydrophobic O₂ preferentially partitions into the membrane, whereas the more hydrophilic NiEDDA preferentially partitions into the solvent (33). As a consequence, membrane-exposed sites become more O₂-accessible whereas solvent-exposed sites exhibit preferential NiEDDA accessibility.

The accessibilities to O₂ and NiEDDA (\(\text{O}_2\) and \(\text{NiEDDA}\), respectively) for all membrane-bound IAPP derivatives are shown in the top panels of Fig. 3A and are summarized by the contrast parameter \(\Phi (\Phi = \ln(1/\text{O}_2/1/\text{NiEDDA}))\). Highlighted in gray is a central region from residue 9 to residue 22. The unique feature of this region is the presence of an extensive stretch of highly periodic oscillations that are perfectly out of phase for the O₂ and NiEDDA accessibilities. The period of the oscillation indicates an \(\alpha\)-helical structure, as maxima and minima are typically spaced three or four residues apart for such structures. The out of phase periodicity of the respective accessibilities reveals an asymmetric solvation in which one face is exposed to the membrane (high \(\text{O}_2\)), while the other face is exposed to the solvent (high \(\text{NiEDDA}\)). The notion of an asymmetrically solvated \(\alpha\)-helix is further supported by the plot that also reveals the \(\alpha\)-helical oscillations for residues 9–22. When residues 9–22 are plotted on an \(\alpha\)-helical wheel, it becomes apparent that the most deeply membrane-embedded residues (Fig. 3B, local \(\Phi\) maxima, red) fall into the hydrophobic face of an amphipathic \(\alpha\)-helix, whereas the solvent-exposed residues fall into the hydrophilic face (local \(\Phi\) minima, blue).

The formation of an \(\alpha\)-helical structure is also in good agreement with the mobility analysis that identified residues 9–20 as the most ordered sites. Only residues 21 and 22 exhibit elevated mobility, suggesting that the C-terminal end of the \(\alpha\)-helix is likely to be frayed and more dynamic.

It has been well established that \(\Phi\) values are directly proportional to the membrane insertion depth and that it is possible to calibrate the immersion depth through the use of spin-labeled lipids (32). Using this approach, we have found that the most lipid-exposed sites (positions 9, 12, 16, and 20) are at a relatively constant immersion depth of \(~16\) Å. Similar immersion depths are characteristic of a peripherally bound peptide rather than of
a transmembrane helix. In the latter case, the immersion depth would be maximal in the center of the helix and would decrease toward the N- and C-terminal regions. Furthermore, the short stretch of ~14 amino acids from residue 9 to residue 22 would be too short to span the bilayer. Thus, the data are not consistent with the formation of a transmembrane helix but rather with an \( \alpha \)-helix that is parallel to the membrane surface.

When building structural models, it is important to consider that the measured immersion depths represent those of the N-O moiety of the R1 side chain. According to crystallographic studies, this group is located ~7–10 Å away from the center of the \( \alpha \)-helix (34). We can therefore estimate that the center of the helix is located at an immersion depth of 6–9 Å below the level of the phosphate groups. The structure of residues 9–22 is schematically indicated in Fig. 4A; the N- and C-terminal regions are not shown because the EPR data did not detect any specifically ordered structure in these regions. It is noteworthy that Arg-11 and His-18 (which is likely to be protonated when in the interfacial region) are located in positions that maximize electrostatic interactions with the negatively charged headgroups/phosphates. Moreover, Phe-15 is located close to the level of the phosphates, a position thought to be favored by aromatic side chains of membrane proteins (35). Collectively, these interactions might contribute to the observed immersion depth of the helix.

**DISCUSSION**

The present study has employed EPR spectroscopy of 29 different spin-labeled hIAPP derivatives and structural modeling to obtain detailed structural information on membrane-bound hIAPP (Fig. 4A). Mobility and accessibility analyses have revealed the formation of an \( \alpha \)-helical structure from residue 9 to residue 22, whereas the N- and C-terminal regions are less ordered and do not exhibit a clearly detectable secondary structure. The central amphipathic \( \alpha \)-helix runs parallel to the membrane and, according to mobility analysis, shows little tertiary and quaternary packing interactions suggesting the formation of a single, predominantly monomeric helix.

Previous predictions of membrane-bound hIAPP using MPEx revealed that an \( \alpha \)-helix composed of residues 10–27 has the highest hydrophobicity and amphipathicity in hIAPP (29). The \( \alpha \)-helical region defined in the present study is entirely contained in this previously identified stretch, but, importantly, it lacks the C-terminal amino acids (residues 23–27). A likely explanation for the somewhat shorter helical structure identified in the present study is the local difference in helical propensity. According to PredictProtein, residues 10–17 exhibit the strongest propensity for \( \alpha \)-helix formation whereas residues 18–37 have only weak helical propensities. In fact, a recent study summarized the accessibility values using the contrast parameter \( \Phi \). Again, helical periodicity is observed in the gray shaded area. Within the \( \alpha \)-helical region, high \( \Phi \) values indicate lipid-exposed sites (red) and low \( \Phi \) values indicate solvent-exposed sites (blue). Sites with in-between \( \Phi \) values are in gray. To illustrate the error associated with the present data the S.E. is shown. The error bars were obtained from accessibility measurements that were repeated at least three times for the lipid and solvent-exposed sites in the \( \alpha \)-helical region. B, the hIAPP residues were plotted on an \( \alpha \)-helical wheel. The lipid-exposed residues lie on one side (red), whereas the solvent-exposed sites (blue) are on the opposite side.
NMR study of rat IAPP revealed that the helical residues identified in the present study can take up partial helical structure in aqueous solution (36).

The present structural information has important implications for the mechanism of aggregation. Residues 20–29 of hIAPP have long been considered a highly amyloidogenic region, and a peptide containing these residues has been shown to readily form amyloid fibrils (37–39). This region also exhibits the largest sequence variation between human and rat IAPP. The region also exhibits the largest sequence variation between human and rat IAPP. The aggregation of the membrane-bound form of hIAPP is expected due to the formation of secondary structure, initiated by residues within the highly amyloidogenic region, that remain unstructured in the membrane-bound state (residues 23–29).

over, membrane interaction also increases the local concentration of hIAPP and reduces the dimensionality of the encounter between multiple hIAPP molecules, which effectively becomes a two-dimensional process. The combination of these factors is likely to be responsible for the pronounced acceleration of membrane-mediated hIAPP misfolding.

Recently, it was concluded that α-helical, membrane-bound hIAPP can form helical oligomers at high protein-to-lipid ratios, and it was suggested that these α-helical oligomers could then transition into β-sheet-containing misfolded forms (30). When combined with the present data, a likely mechanism for aggregation and misfolding would be the initiation of β-sheet formation in the C-terminus of such helical bundles or other transient complexes (Fig. 4C). This notion is further supported by the finding that rat IAPP, which also forms an α-helical structure on membranes, contains three prolines in the critical region (residues 20–29) and does not undergo membrane-mediated misfolding. Similarly, truncated hIAPP containing residues 1–24 readily takes up an α-helical structure but does not readily undergo membrane-mediated aggregation, as judged by thioflavin T fluorescence.3 Subsequent to the formation of the initial, presumably α-helix- and β-sheet-containing, oligomers, the α-helical structure must then be lost, because previous CD analysis shows that gain of β-sheet structure coincides with the loss of α-helical structure. Furthermore, it is now well established that the β-sheet-containing core region of hIAPP fibrils extends well beyond residues 20–29 and includes most, if not all, of the residues that participate in α-helix formation (29, 41).

Our previous study revealed that the most rapid aggregation occurs at a POPS percentage of 25%. These data are consistent with the model in Fig. 4A, wherein the α-helical form represents a transient intermediate. In the concentration range between 0 and 25% POPS, an increase in the amount of POPS increases the amount of α-helix formation and thereby promotes misfolding via the mechanism shown in Fig. 4C. At higher concentrations of POPS, such as those used in the present study, the α-helical form becomes increasingly more stable. This stabilization should inhibit the transition from mixed α/β

3 M. Apostolidou and R. Langen, unpublished results.
oligomers to predominantly β-sheet oligomers. In cells, the density of POPS (or other negatively charged lipids) varies significantly but is typically less than 25%. Consequently, we expect that the α-helical form described here will be rather short-lived and, presumably, will readily transition into the misfolded state. Such a mechanism should be particularly important for cytosolic hIAPP (7, 9, 42), and prevention of the misfolding pathway outlined in Fig. 4C could therefore ameliorate the toxic effects of hIAPP.

Acknowledgment—We thank Diana Gegala for assistance during the preparation of the manuscript.

REFERENCES
1. Soto, C. (2003) Nat. Rev. Neurosci. 4, 49–60
2. Hall, R. L., Westermark, G. T., Westermark, P., and Kahn, S. E. (2004) J. Clin. Endocrinol. Metab. 89, 3629–3643
3. Kahn, S. E., Andrikopoulos, S., and Verchere, C. B. (1999) Diabetes 48, 241–253
4. Janson, J., Ashley, R. H., Harrison, D., McIntyre, S., and Butler, P. C. (1999) Diabetes 48, 491–498
5. Kurganov, B., Doh, M., and Arispe, N. (2004) Biochemistry 43, 3901–3906
6. Ritzel, R. A., and Butler, P. C. (2003) Diabetes 52, 1701–1708
7. O’Brien, T. D., Butler, P. C., Kreutter, D. K., Kane, L. A., and Eberhardt, N. L. (1995) Ann. J. Pathol. 147, 609–616
8. Hiddinga, H. J., and Eberhardt, N. L. (1999) Ann. J. Pathol. 154, 1077–1088
9. Janson, J., Soeller, W. C., Roche, P. C., Nelson, R. T., Torchia, A. J., Kreutter, D. K., and Butler, P. C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 7283–7288
10. Butler, A. E., Jang, J., Gurlo, T., Carty, M. D., Soeller, W. C., and Butler, P. C. (2004) Diabetes 53, 1509–1516
11. Verchere, C. B., D’Alessio, D. A., Palmer, R. D., Weir, G. C., Bonner-Weir, S., Baskin, D. G., and Kahn, S. E. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 3492–3496
12. Soeller, W. C., Janson, J., Hart, S. E., Parker, J. C., Carty, M. D., Stevenson, R. W., Kreutter, D. K., and Butler, P. C. (1998) Diabetes 47, 743–750
13. Hoppener, J. W., Oosterwik, C., Nieuwenhuis, M. G., Posthuma, G., Thijssen, J. H., Vroom, T. M., Ahren, B., and Lips, C. J. (1999) Diabetologia 42, 427–434
14. Caughey, B., and Lansbury, P. T. (2003) Annu. Rev. Neurosci. 26, 267–298
15. Jayasinghe, S. A., and Langen, R. (2007) Biochim. Biophys. Acta 1768, 2002–2009
16. Anguiano, M., Nowak, R. W., and Lansbury, P. T., Jr. (2002) Biochemistry 41, 11338–11343
17. Arispe, N., Pollard, H. B., and Rojas, E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 10573–10577
18. Volles, M. J., Lee, S. J., Rochet, J.-C., Shtilerman, M. D., Ding, T. T., Kessler, J. C., and Lansbury, P. T., Jr. (2001) Biochemistry 40, 7812–7819
19. Lashuel, H. A., and Lansbury, P. T. (2006) Q. Rev. Biophys. 1–35
20. Kurnasov, B., Doh, M., and Arispe, N. (2004) Peptides 25, 217–232
21. Kazlauskaitė, J., Sanghera, N., Sylvestre, I., Venien-Bryan, C., and Pinheiro, T. I. (2003) Biochemistry 42, 3295–3304
22. Matsuzaki, K., and Horikiri, C. (1999) Biochemistry 38, 4137–4142
23. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) J. Biol. Chem. 273, 9443–9449
24. 24. Knight, J. D., and Miranker, A. D. (2004) J. Mol. Biol. 341, 1175–1187
25. Volles, M. J., Lee, S. J., Ding, T. T., Kessler, J. C., and Lansbury, P. T., Jr. (2001) Biochemistry 40, 7812–7819
26. Lashuel, H. A., and Lansbury, P. T. (2005) Q. Rev. Biophys. 1–35
27. Kurnasov, B., Doh, M., and Arispe, N. (2004) Peptides 25, 217–232
28. Kazlauskaitė, J., Sanghera, N., Sylvestre, I., Venien-Bryan, C., and Pinheiro, T. I. (2003) Biochemistry 42, 3295–3304
29. Matsuzaki, K., and Horikiri, C. (1999) Biochemistry 38, 4137–4142
30. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) J. Biol. Chem. 273, 9443–9449
31. Knight, J. D., and Miranker, A. D. (2004) J. Mol. Biol. 341, 1175–1187
32. Volles, M. J., Lee, S. J., Ding, T. T., Kessler, J. C., and Lansbury, P. T., Jr. (2001) Biochemistry 40, 7812–7819
33. Lashuel, H. A., and Lansbury, P. T. (2005) Q. Rev. Biophys. 1–35
34. Kurnasov, B., Doh, M., and Arispe, N. (2004) Peptides 25, 217–232
35. Kazlauskaitė, J., Sanghera, N., Sylvestre, I., Venien-Bryan, C., and Pinheiro, T. I. (2003) Biochemistry 42, 3295–3304
36. Matsuzaki, K., and Horikiri, C. (1999) Biochemistry 38, 4137–4142
37. Davidson, W. S., Jonas, A., Clayton, D. F., and George, J. M. (1998) J. Biol. Chem. 273, 9443–9449
38. Knight, J. D., and Miranker, A. D. (2004) J. Mol. Biol. 341, 1175–1187
39. Volles, M. J., Lee, S. J., Ding, T. T., Kessler, J. C., and Lansbury, P. T., Jr. (2001) Biochemistry 40, 7812–7819
40. Lashuel, H. A., and Lansbury, P. T. (2005) Q. Rev. Biophys. 1–35